Vyvanse Generics Get Green Light To Enter US

More Than A Dozen Firms Receive FDA Approvals For Lisdexamfetamine Rivals

One of 2023’s most significant loss-of-exclusivity opportunities for the generics industry has come to pass, after the US FDA approved more than a dozen rivals to Takeda’s blockbuster ADHD treatment Vyvanse.

Multiple Thumbs
The FDA has approved a swathe of lisdexamfetamine generics • Source: Shutterstock

One of this year’s biggest loss-of-exclusivity opportunities for the US off-patent industry has come to pass, after the US Food and Drug Administration approved more than a dozen generic rivals to Takeda’s blockbuster attention-deficit/hyperactivity disorder treatment Vyvanse (lisdexamfetamine).

Generic versions of lisdexamfetamine capsules in 10mg, 20mg, 30mg 40mg, 50mg, 60mg and 70mg strengths have been approved by the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin